Prevalence and association of macrolide-lincosamide-streptogramin B (MLSB) resistance with resistance to moxifloxacin in Clostridium difficile

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 3, 2003, Pages 599-603

  Ackermann, Grit ^a   Degner, Angelika ^a   Cohen, Stuart H ^b   Silva Jr , Joseph ^b   Rodloff, Arne C ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antimicrobials; Clostridium difficile; Susceptibility

Indexed keywords

BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; DNA; ERYTHROMYCIN; LINCOSAMIDE; MACROLIDE; METHYLTRANSFERASE; METRONIDAZOLE; MIKAMYCIN B; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DIARRHEA; DNA SEQUENCE; GENETIC ANALYSIS; GERMANY; HOSPITAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CLOSTRIDIUM DIFFICILE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FLUOROQUINOLONES; HUMANS; MACROLIDES; PREVALENCE; QUINOLINES; STREPTOGRAMIN B;

EID: 0037342194     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg112     Document Type: Article

References (23)

1. McFarland, L. V., Mulligan, M. E., Kwok, R. Y. Y. & Stamm, W. E. (1989). Nosocomial acquisition of Clostridium difficile infection. New England Journal of Medicine 320, 204-10.
2. Kelly, C. P., Pothoulakis, C. & LaMont, J. T. (1994). Clostridium difficile colitis. New England Journal of Medicine 330, 257-62.
3. Johnson, S., Samore, M. H., Farrow, K. A., Killgore, G. E., Tenover, F. C., Lyras, D. et al. (1999). Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. New England Journal of Medicine 341, 1645-51.
4. Barbut, F., Decré, D., Burghoffer, B., Lesage, D., Delisle, F., Lalande, V. et al. (1999). Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrobial Agents and Chemotherapy 43, 2607-11.
5. Brazier, J. S., Fawley, W., Freeman, J. & Wilcox, M. H. (2001). Reduced susceptibility of Clostridium difficile to metronidazole. Journal of Antimicrobial Chemotherapy 48, 741-2.
6. Jang, S. S., Hansen, L. M., Breher, J. E., Riley, D. A., Magdesian, K. G., Tang, Y. J. et al. (1997). Antimicrobial susceptibilities of equine isolates of Clostridium difficile and molecular characterization of metronidazole-resistant strains. Clinical Infectious Diseases 25, S266-7.
7. Peláez, T., Alonso, R., Pérez, C., Alcalá, L., Cuevas, O. & Bouza, E. (2002). In vitro activity of linezolid against Clostridium difficile. Antimicrobial Agents and Chemotherapy 46, 1617-8.
8. Ackermann, G., Tang, Y. T., Kueper, R., Heisig, P., Rodloff, A. C., Silva, J., Jr et al. (2001). Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in the gyrA gene. Antimicrobial Agents and Chemotherapy 4, 2348-53.
9. Wilcox, M. H., Fawley, W., Freeman, J. & Brayson, J. (2000). In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. Journal of Antimicrobial Chemotherapy 46, 551-5.
10. Arthur, M., Brisson-Noël, A. & Courvalin, P. (1987). Origin and evolution of genes specifying resistance to macrolide, lincosamide and streptogramin antibiotics: data and hypotheses. Journal of Antimicrobial Chemotherapy 20, 783-802.
11. Sutcliffe, J., Tait-Kamradt, A. & Wondrack, L. (1996). Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrobial Agents and Chemotherapy 40, 1817-24.
12. Weisblum, B. (1995). Erythromycin resistance by ribosome modification. Antimicrobial Agents and Chemotherapy 39, 577-85.
13. Wüst, J. & Hardegger, U. (1983). Transferable resistance to clindamycin, erythromycin, and tetracycline in Clostridium difficile. Antimicrobial Agents and Chemotherapy 2, 784-6.
14. Farrow, K. A., Lyras, D. & Rodd, J. I. (2001). Genomic analysis of the erythromycin resistance element Tn5398 from Clostridium difficile. Microbiology 147, 2717-28.
15. Mullany, P., Wilks, M. & Tabaqchali, S. (1995). Transfer of macrolide-lincosamide-streptogramin B (MLS) resistance in Clostridium difficile is linked to a gene homologous with toxin A and is mediated by a conjugative transposon, Tn5398. Journal of Antimicrobial Chemotherapy 35, 305-15.
16. Farrow, K. A., Lyras, D. & Rood, J. I. (2000). The macrolide-lincosamide-streptogramin B resistance determinant from Clostridium difficile 630 contains two erm(B) genes. Antimicrobial Agents and Chemotherapy 44, 411-3.
17. B) resistance determinants in strains of Clostridium difficile. Microbial Drug Resistance 8, 45-53.
18. George, W. L., Sutter, V. L., Citron, D. & Finegold, S. M. (1979). Selective and differential medium for the isolation of Clostridium difficile. Journal of Clinical Microbiology 9, 214-9.
19. Cohen, S. H., Tang, Y. J. & Silva, J., Jr (2000). Analysis of the pathogenicity locus in Clostridium difficile strains. Journal of Infectious Diseases 181, 659-63.
20. DIN, Deutsches Institut für Normung e.V. (2000). Medizinische Mikrobiologie und Immunologie: diagnostische Verfahren. Beuth, Berlin, Wien, Zürich.
21. Stubbs, S. L. J., Brazier, J. S., O'Neill, G. L. & Duerden, B. I. (1999). PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. Journal of Clinical Microbiology 37, 461-3.
22. Ferrero, L., Cameron, B., Manse, B., Lagneaux, D., Crouzet, J., Famechon, A. et al. (1994). Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Molecular Microbiology 13, 641-53.
23. Hooper, D. C. & Wolfson, J. S. (1993). Mechanisms of bacterial resistance to quinolones. In Quinolone Antibacterial Agents, 2nd edn (Hooper, D. C. & Wolfson, J. S., Eds), pp. 97-118. American Society for Microbiology, Washington, DC, USA.